Investment Thesis
Century Therapeutics exhibits a strong balance sheet with excellent liquidity and 1556.8% revenue growth, but the company is burning $25.8M annually in negative free cash flow against only $51M cash reserves, limiting runway to approximately 2 years. Without achieving profitability or securing additional funding, the company faces significant execution risk despite adequate near-term financial capacity.
Strengths
- Exceptional balance sheet: $264.7M stockholders' equity with minimal debt (0.04x D/E ratio)
- Outstanding liquidity ratios (10.25x current and quick ratios) providing operational flexibility
- Dramatic revenue growth of 1556.8% YoY indicating major partnership, licensing, or clinical milestone achievements
- Loss per share improving 91.3% YoY, showing trajectory toward reduced burn rate
Risks
- Severe negative free cash flow of -$25.8M annually with only 2-year cash runway at current burn rate
- Company unprofitable across all metrics (operating margin -21.7%, net margin -19.8%, ROE -8.2%, ROA -6.6%)
- Unusual revenue recognition pattern without corresponding profitability suggests one-time partnership/licensing revenue rather than sustainable operating model
- No gross profit reporting and inability to demonstrate unit economics clarity
Key Metrics to Watch
- Operating cash flow trajectory and path to breakeven
- Cash balance depletion rate and timeline to capital raise needs
- Revenue sustainability and recurring vs. non-recurring revenue breakdown
- Clinical trial progress and regulatory milestones for pipeline products
Financial Metrics
Revenue
109.2M
Net Income
-21.6M
EPS (Diluted)
$-0.11
Free Cash Flow
-25.8M
Total Assets
326.6M
Cash
51.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-21.7%
Net Margin
-19.8%
ROE
-8.2%
ROA
-6.6%
FCF Margin
-23.7%
Balance Sheet & Liquidity
Current Ratio
10.25x
Quick Ratio
10.25x
Debt/Equity
0.04x
Debt/Assets
18.9%
Interest Coverage
-43.86x
Long-term Debt
10.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:34:30.997778 |
Data as of: 2026-03-31 |
Powered by Claude AI